Victoza liraglutide: Phase II data

The double-blind, U.K. Phase II LEAN trial in 52 overweight patients with NASH showed that once-daily 1.8 mg subcutaneous liraglutide for 48 weeks met the primary endpoint of a higher rate of resoluti...